The changes in plasma serotonin levels after hormone therapy and their relationship with estrogen responsiveness on bone in postmenopausal women.
Abstract
CONTEXT
Selective serotonin reuptake inhibitors have shown to be associated with an increased risk of fractures. It has been suggested
that circulating serotonin is an important regulatory factor and that estrogen may regulate bone metabolism through the serotonin
pathway.
OBJECTIVE
Our objective was to determine the association between plasma serotonin level and bone turnover before and after hormone therapy
(HT) in postmenopausal women.
PARTICIPANTS AND DESIGN
In this parallel comparative study using age-matched controls, 80 postmenopausal women (21 control, 59 receiving HT) aged
46-64 yr were assessed. The plasma levels of serotonin, serum concentrations of osteocalcin and carboxyterminal telopeptides,
and bone mineral density (BMD) were measured at baseline and after 3 months and 1 yr of HT.
RESULTS
The plasma serotonin level was significantly correlated with serum total alkaline phosphatase level at baseline (r = -0.223,
P = 0.048) but not with serum osteocalcin (r = -0.217, P = 0.056) or carboxyterminal telopeptides (r = -0.217, P = 0.054).
There was no significant association between baseline serotonin and BMD measured at the spine or femur. The median decrements
of circulating serotonin from baseline were -9.3% (interquartile range -34.0 to 53.6%) and -7.2% (-25.5 to 64.5%) at 3 months
and 1 yr of HT, respectively. These changes were not significantly different from those in the control group. The short-term
changes of circulating serotonin at 3 months after HT did not show significant association with the changes in BMD measured
at the lumbar spine or proximal femur 1 year after HT.
CONCLUSIONS
Our results suggest that circulating serotonin may reflect bone turnover status, but it is not a strong enough predictor of
bone loss to use as a bone marker. Moreover, serial measurements of plasma serotonin after short-term treatment with estrogen
cannot predict the long-term responsiveness of bone to estrogen, suggesting that the bone-preserving effect of estrogen is
independent of the peripheral action of serotonin on bone.
Links
Authors
Kim HY, Park MH, Yoon HK, Han KO
Institution
Department of Endocrinology and Metabolism, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine, 1-19 Mukjung Dong, Choong Gu, Seoul 100-380, Korea.
Source
The Journal of clinical endocrinology and metabolism 97:6 2012 Jun pg 1986-94MeSH
Biological MarkersBone Density
Bone Remodeling
Collagen Type I
Estrogen Replacement Therapy
Estrogens
Female
Humans
Middle Aged
Osteocalcin
Peptides
Postmenopause
Predictive Value of Tests
Serotonin
Pub Type(s)
Journal ArticleResearch Support, Non-U.S. Gov't
Language
eng
PubMed ID
22442273
Log In

